US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

4.28

-0.0300-0.70%

Post-market: 4.280.00000.00%19:50 EDT

Volume:181.49K

Turnover:774.50K

Market Cap:232.86M

PE:-0.41

High:4.49

Open:4.29

Low:4.16

Close:4.31

Loading ...

Overview Company News Filings

Acelyrin Reaffirms Merger Deal With Alumis

MT Newswires Live

REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer

Alumis Inc. Announces Merger with ACELYRIN, Inc.

BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger

Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger

BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

THOMSON REUTERS

Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

THOMSON REUTERS

Press Release: ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Promising Prospects for Alumis Inc.’s TYK2 Inhibitor A-005: Analyst Reiterates Buy Rating with $19 Price Target

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at Actrims Forum 2025 Supporting Potential of a-005 as First-in-Class CNS Penetrant Tyk2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

THOMSON REUTERS

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis Inc. Approves New Severance and Control Plan

Acelyrin Stock Jumps on Concentra Acquisition Interest

BUZZ-Acelyrin jumps on Concentra Biosciences' buyout offer amid pending merger with Alumis

Acelyrin Receives Unsolicited Buyout Offer From Concentra Biosciences

MT Newswires Live

Analysts Offer Insights on Materials Companies: Alumis Inc. (ALMS) and Martin Marietta Materials (MLM)

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ALMS/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":4.28,"timestamp":1745611200000,"preClose":4.31,"halted":0,"volume":181491,"hourTrading":{"tag":"盘后","latestPrice":4.28,"preClose":4.28,"latestTime":"19:50 EDT","volume":1161,"amount":4970.348,"timestamp":1745625044435},"delay":0,"floatShares":4764683,"shares":54407327,"eps":-10.381567,"marketStatus":"Market Closed","change":-0.03,"latestTime":"04-25 16:00:00 EDT","open":4.29,"high":4.4884,"low":4.16,"amount":774495.7823460001,"amplitude":0.076195,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.381567,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":4.31,"preHourTrading":{"tag":"盘前","latestPrice":4.36,"preClose":4.31,"latestTime":"09:29 EDT","volume":122,"amount":540.441944,"timestamp":1745587799998},"postHourTrading":{"tag":"盘后","latestPrice":4.28,"preClose":4.28,"latestTime":"19:50 EDT","volume":1161,"amount":4970.348,"timestamp":1745625044435},"volumeRatio":0.549558,"impliedVol":0.8308,"impliedVolPercentile":0.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":4764683,"roa":"-87.31%","roe":"-198.66%","lyrEps":-10.381567,"volumeRatio":0.549558,"shares":54407327,"dividePrice":0,"high":4.4884,"amplitude":0.076195,"preClose":4.31,"low":4.16,"week52Low":3.18,"pbRate":"0.90","week52High":13.53,"institutionHeld":0,"latestPrice":4.28,"eps":-10.381567,"divideRate":0,"volume":181491,"delay":0,"ttmEps":-10.381567,"open":4.29,"prevYearClose":7.86,"prevWeekClose":5,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":5,"twentyDayClose":4.7,"sixtyDayClose":6.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516608325","title":"Acelyrin Reaffirms Merger Deal With Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608325","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516608325?lang=en_us&edition=fundamental","pubTime":"2025-03-04 23:10","pubTimestamp":1741101018,"startTime":"0","endTime":"0","summary":"Acelyrin (SLRN) and Alumis (ALMS) reaffirmed Tuesday their commitment to merge in an all-stock transaction, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","SLRN","BK4007","BK4139"],"gpt_icon":0},{"id":"2516067205","title":"REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516067205","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516067205?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:44","pubTimestamp":1741099479,"startTime":"0","endTime":"0","summary":"REFILE-BUZZ-Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offerCorrects company name to \"Concentra\" in bullet 3, corrects typographical error in bullet 5** Shares of dru","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN1F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEM","SLRN","ALMS","CON"],"gpt_icon":0},{"id":"2516777456","title":"Alumis Inc. Announces Merger with ACELYRIN, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516777456","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516777456?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:28","pubTimestamp":1741098505,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has shared an update. On March 4, 2025, Alumis Inc. and ACELYRIN, Inc. announced their commitment to merge in an all-stock ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-inc-announces-merger-with-acelyrin-inc-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-inc-announces-merger-with-acelyrin-inc-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2516383674","title":"BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516383674","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516383674?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:07","pubTimestamp":1741097248,"startTime":"0","endTime":"0","summary":"BRIEF-Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis MergerMarch 4 (Reuters) - Alumis Inc ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA475HLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2516674655","title":"Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674655","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674655?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:06","pubTimestamp":1741097208,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) and ACELYRIN (SLRN) reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biop...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acelyrin-alumis-reaffirm-strategic-financial-rationale-of-proposed-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acelyrin-alumis-reaffirm-strategic-financial-rationale-of-proposed-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS","BK4139","SLRN"],"gpt_icon":0},{"id":"2516748486","title":"BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516748486","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516748486?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:06","pubTimestamp":1741097191,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed MergerMarch 4 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND ACELYRIN REAFFIRM STRATEGIC AND FINANCIAL RATIONALE OF PROPOSED ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA48S77V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4139","SLRN","BK4007"],"gpt_icon":0},{"id":"2516783671","title":"ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516783671","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516783671?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:01","pubTimestamp":1741096860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA149XQ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007","SLRN","BK4139"],"gpt_icon":0},{"id":"2516751671","title":"Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516751671","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516751671?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:01","pubTimestamp":1741096860,"startTime":"0","endTime":"0","summary":"Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet. LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025  -- ACELYRIN, INC.  and Alumis Inc.  today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases.\"The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that stockholders support the planned merger,\" said Mina Kim, Chief Executive Officer of ACELYRIN. \"We chose to enter into the merger agreement with Alumis after a comprehensive assessment of strategic alternatives, and believe this is the best outcome for ACELYRIN stockholders. We're excited about the combined company's potential for significant value creation as a result of its expanded portfolio, strong financial foundation and proven leadership.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2516671164","title":"ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516671164","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516671164?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA475HLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ALMS","SLRN"],"gpt_icon":0},{"id":"2516867175","title":"Press Release: ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2516867175","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516867175?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger. All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders. LOS ANGELES, March 04, 2025  -- ACELYRIN, INC. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. .The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","ALMS","BK4007","BK4139"],"gpt_icon":0},{"id":"2516347682","title":"Promising Prospects for Alumis Inc.’s TYK2 Inhibitor A-005: Analyst Reiterates Buy Rating with $19 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2516347682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516347682?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:27","pubTimestamp":1741001224,"startTime":"0","endTime":"0","summary":"In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price targ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-prospects-for-alumis-inc-s-tyk2-inhibitor-a-005-analyst-reiterates-buy-rating-with-19-price-target?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-prospects-for-alumis-inc-s-tyk2-inhibitor-a-005-analyst-reiterates-buy-rating-with-19-price-target?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2514327978","title":"Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2514327978","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514327978?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:08","pubTimestamp":1740751680,"startTime":"0","endTime":"0","summary":"– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension  study in adults with moderate-to-severe plaque psoriasis –。– Additional Phase 2e-poster presentations to describe patient-reported outcomes, disease biomarker activity and pharmacokinetic data of ESK-001 in psoriasis patients –。“We are pleased to have these Phase 2 OLE data for ESK-001 selected for late-breaking oral and e-poster presentations at the annual AAD meeting and the opportunity to share these important results with the dermatology community,” said Martin Babler, President and Chief Executive Officer of Alumis. \"In addition, as a result of our program execution and the strong interest from patients and clinical investigators, we have accelerated our expected topline Phase 3 clinical data milestone to the first quarter of 2026.”About ESK-001Alumis’ lead clinical candidate, ESK-001, is a highly selective, next-generation oral TYK2 inhibitor that is designed to correct immun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-announces-breaker-psoriasis-presentation-140800310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","ALMS","AFG","BK4007","BK4117"],"gpt_icon":0},{"id":"2514935838","title":"Alumis Presents Additional Phase 1 Data at Actrims Forum 2025 Supporting Potential of a-005 as First-in-Class CNS Penetrant Tyk2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2514935838","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514935838?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:15","pubTimestamp":1740690901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nTUA4TV7L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2514358922","title":"Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358922","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358922?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:15","pubTimestamp":1740690900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025  -- Alumis Inc.  , a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the Company will give two data presentations on A-005, a potent, selective, central nervous system  penetrant tyrosine kinase 2  inhibitor, on Friday, February 28, 2025, at the 10th Annual Americas Committee for Treatment and Research in Multiple Sclerosis  Forum 2025.“These data demonstrate that A-005 potently inhibits TYK2-specific signaling in immune cells and CNS resident cells, targeting pro-inflammatory cytokine pathways implicated in the pathology of neuroinflammatory diseases,” said Jrn Drappa, M.D., Alumis’ Chief Medical Officer. “As the first reported allosteric TYK2 inhibitor with demonstrated ability to cross the blood-brain barrier, A-005 represents a novel approach to potentially treating a bro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-presents-additional-phase-1-211500176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4179","FET","PD","BK4135","BK4181","LU1169590202.USD","BK4218","ALMS","BK4007","BK4023","CNS","LU1169589451.USD"],"gpt_icon":0},{"id":"2513121021","title":"Alumis Inc. Approves New Severance and Control Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2513121021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513121021?lang=en_us&edition=fundamental","pubTime":"2025-02-22 05:31","pubTimestamp":1740173482,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Alumis Inc. ( ($ALMS) ). On February 18, 2025, Alumis Inc. approved a Severance and Change in Control Plan to p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-inc-approves-new-severance-and-control-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-inc-approves-new-severance-and-control-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2513429571","title":"Acelyrin Stock Jumps on Concentra Acquisition Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2513429571","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513429571?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:16","pubTimestamp":1740147360,"startTime":"0","endTime":"0","summary":"Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share.The stock was up 14% at $2.48 in premarket trading. Shares had fallen 31% year to date when the market closed Thursday.The Los Angeles-based late-stage biopharma company said Friday morning that Concentra's all-cash proposal includes a right to receive 80% of proceeds from any out-license or disposition of Acelyrin's development programs or intellectual property.The offer comes after Acelyrin agreed earlier this month to merge with Alumis in an all-stock deal that is expected to close in the second quarter.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","SLRN","BK4139"],"gpt_icon":0},{"id":"2513614232","title":"BUZZ-Acelyrin jumps on Concentra Biosciences' buyout offer amid pending merger with Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2513614232","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513614232?lang=en_us&edition=fundamental","pubTime":"2025-02-21 20:06","pubTimestamp":1740139592,"startTime":"0","endTime":"0","summary":"BUZZ-Acelyrin jumps on Concentra Biosciences' buyout offer amid pending merger with Alumis** Shares of drug developer Acelyrin SLRN.O rise 17.05% to $2.54 premarket** SLRN confirms that private affili","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3N3PC0YI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","SLRN","CON","SEM","BK4007","BK4139","BK4185"],"gpt_icon":0},{"id":"2513254762","title":"Acelyrin Receives Unsolicited Buyout Offer From Concentra Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2513254762","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513254762?lang=en_us&edition=fundamental","pubTime":"2025-02-21 17:28","pubTimestamp":1740130109,"startTime":"0","endTime":"0","summary":"Acelyrin  said late Thursday it has received an unsolicited indication of interest from Tang Capital Partners-backed Concentra Biosciences to acquire all of its outstanding shares for $3.00 per share in cash, plus a contingent value right to receive 80% of net proceeds from any out-license or disposition of its development programs or intellectual property.Acelyrin said it agreed Feb. 6 to an all-stock merger with Alumis  in a deal expected to close in Q2.The company said its board is committed to acting in the interests of shareholders and will make a further announcement on the matter \"in due course.\"Shares of Acelyrin rose more than 12% in recent premarket activity Friday.Price: 2.45, Change: +0.28, Percent Change: +12.90","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","BK4007","SLRN","BK4139"],"gpt_icon":0},{"id":"2510809870","title":"Analysts Offer Insights on Materials Companies: Alumis Inc. (ALMS) and Martin Marietta Materials (MLM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510809870","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510809870?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:13","pubTimestamp":1739268814,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Alumis Inc. (ALMS – Research Report) and Martin Marie...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-materials-companies-alumis-inc-alms-and-martin-marietta-materials-mlm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-materials-companies-alumis-inc-alms-and-martin-marietta-materials-mlm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKG","LU0053666078.USD","LU2237438978.USD","BK4585","BK4544","MLM","BK4007","BK4548","BK4588","SG9999001077.SGD","BK4011","ALMS"],"gpt_icon":0},{"id":"2510297813","title":"Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2510297813","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510297813?lang=en_us&edition=fundamental","pubTime":"2025-02-11 05:45","pubTimestamp":1739223900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Feb.  10, 2025  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/10/3023818/0/en/Alumis-to-Present-at-Oppenheimer-35th-Annual-Healthcare-Life-Sciences-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007","HCSG","BK4127","BK4137","OPY"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":99,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-04-24","current":-0.870937,"percent":0.963351,"low":-5.220865,"twenty":-3.461615,"median":-2.006318,"eighty":-1.170751,"high":-0.660137,"avg":-2.364432,"sd":1.067026,"marketCap":256258510},"quantilePoints":[{"date":"2024-06-28","current":-5.220865,"twenty":-5.220865,"median":-5.220865,"eighty":-5.220865,"marketCap":881360393},{"date":"2024-07-05","current":-3.577828,"twenty":-4.31182,"median":-3.851156,"eighty":-3.577828,"marketCap":603991092},{"date":"2024-07-12","current":-3.798947,"twenty":-4.001025,"median":-3.825051,"eighty":-3.577828,"marketCap":641319297},{"date":"2024-07-15","current":-3.405847,"twenty":-3.980142,"median":-3.798947,"eighty":-3.577828,"marketCap":574958044},{"date":"2024-08-02","current":-4.08515,"twenty":-4.063676,"median":-3.825051,"eighty":-3.577828,"marketCap":689634611},{"date":"2024-08-09","current":-3.930629,"twenty":-4.063676,"median":-3.914533,"eighty":-3.58397,"marketCap":663549141},{"date":"2024-08-16","current":-3.699952,"twenty":-4.025518,"median":-3.855481,"eighty":-3.617622,"marketCap":699416662},{"date":"2024-08-23","current":-3.709695,"twenty":-3.973459,"median":-3.817957,"eighty":-3.659922,"marketCap":701258562},{"date":"2024-08-30","current":-3.67516,"twenty":-3.943506,"median":-3.741353,"eighty":-3.65762,"marketCap":694730166},{"date":"2024-09-06","current":-3.390241,"twenty":-3.930629,"median":-3.739914,"eighty":-3.608539,"marketCap":640870897},{"date":"2024-09-13","current":-3.240587,"twenty":-3.915649,"median":-3.699952,"eighty":-3.511116,"marketCap":612581180},{"date":"2024-09-20","current":-3.272245,"twenty":-3.914533,"median":-3.679477,"eighty":-3.395997,"marketCap":618565543},{"date":"2024-09-27","current":-3.444923,"twenty":-3.859807,"median":-3.655014,"eighty":-3.33556,"marketCap":651207524},{"date":"2024-10-04","current":-2.886598,"twenty":-3.851156,"median":-3.617387,"eighty":-3.295269,"marketCap":545665119},{"date":"2024-10-11","current":-2.961425,"twenty":-3.850149,"median":-3.577828,"eighty":-3.211808,"marketCap":559809977},{"date":"2024-10-18","current":-3.200296,"twenty":-3.817957,"median":-3.47802,"eighty":-3.18015,"marketCap":604964718},{"date":"2024-10-25","current":-3.444923,"twenty":-3.798947,"median":-3.465068,"eighty":-3.200296,"marketCap":651207524},{"date":"2024-10-31","current":-3.231953,"twenty":-3.752872,"median":-3.462191,"eighty":-3.209506,"marketCap":610949081},{"date":"2024-11-08","current":-3.367218,"twenty":-3.741353,"median":-3.447801,"eighty":-3.218715,"marketCap":636518633},{"date":"2024-11-15","current":-2.144174,"twenty":-3.741353,"median":-3.444923,"eighty":-3.209506,"marketCap":511972947},{"date":"2024-11-22","current":-2.15101,"twenty":-3.739051,"median":-3.433411,"eighty":-3.073089,"marketCap":513605166},{"date":"2024-11-29","current":-2.109995,"twenty":-3.736748,"median":-3.419021,"eighty":-3.008623,"marketCap":503811848},{"date":"2024-12-06","current":-1.964163,"twenty":-3.720056,"median":-3.405847,"eighty":-2.970059,"marketCap":468991158},{"date":"2024-12-13","current":-1.989228,"twenty":-3.703849,"median":-3.378729,"eighty":-2.667081,"marketCap":474975964},{"date":"2024-12-20","current":-1.966442,"twenty":-3.691984,"median":-3.312536,"eighty":-2.153744,"marketCap":469535232},{"date":"2024-12-27","current":-1.916313,"twenty":-3.685521,"median":-3.301025,"eighty":-2.142807,"marketCap":457565620},{"date":"2025-01-03","current":-1.873019,"twenty":-3.682067,"median":-3.286635,"eighty":-2.0626,"marketCap":447228227},{"date":"2025-01-10","current":-1.752253,"twenty":-3.67516,"median":-3.266489,"eighty":-2.0029,"marketCap":418392344},{"date":"2025-01-17","current":-1.775039,"twenty":-3.672282,"median":-3.247782,"eighty":-1.966442,"marketCap":423833077},{"date":"2025-01-24","current":-1.497048,"twenty":-3.658468,"median":-3.227637,"eighty":-1.954138,"marketCap":357456138},{"date":"2025-01-31","current":-1.531227,"twenty":-3.654166,"median":-3.211808,"eighty":-1.919959,"marketCap":365617237},{"date":"2025-02-07","current":-1.501605,"twenty":-3.631778,"median":-3.162882,"eighty":-1.882133,"marketCap":358544284},{"date":"2025-02-14","current":-1.162092,"twenty":-3.62163,"median":-3.070787,"eighty":-1.832004,"marketCap":277477367},{"date":"2025-02-21","current":-1.168928,"twenty":-3.613315,"median":-3.018984,"eighty":-1.784609,"marketCap":279109587},{"date":"2025-02-28","current":-1.064112,"twenty":-3.590112,"median":-2.978693,"eighty":-1.743594,"marketCap":254082217},{"date":"2025-03-07","current":-1.162092,"twenty":-3.577828,"median":-2.970059,"eighty":-1.696654,"marketCap":277477367},{"date":"2025-03-14","current":-1.045883,"twenty":-3.561975,"median":-2.844868,"eighty":-1.612801,"marketCap":249729630},{"date":"2025-03-21","current":-0.660137,"twenty":-3.530406,"median":-2.358363,"eighty":-1.527581,"marketCap":194234157},{"date":"2025-03-28","current":-0.869088,"twenty":-3.513232,"median":-2.153288,"eighty":-1.493402,"marketCap":255714436},{"date":"2025-04-04","current":-1.579152,"twenty":-3.504209,"median":-2.144174,"eighty":-1.320049,"marketCap":464638572},{"date":"2025-04-11","current":-1.262952,"twenty":-3.478882,"median":-2.109995,"eighty":-1.320049,"marketCap":371602043},{"date":"2025-04-17","current":-0.937506,"twenty":-3.463917,"median":-2.033661,"eighty":-1.195689,"marketCap":275845147},{"date":"2025-04-24","current":-0.870937,"twenty":-3.461615,"median":-2.006318,"eighty":-1.170751,"marketCap":256258510}],"updateTime":1745640576777}}}